Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc

被引：0
作者：
机构：
来源：
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN) | 2019年 / 1021卷
关键词：
CELL LUNG-CANCER; OPEN-LABEL PHASE-3; ADVANCED MELANOMA; COST-EFFECTIVENESS; PEMBROLIZUMAB; NIVOLUMAB; CHEMOTHERAPY; IPILIMUMAB; DOCETAXEL; MULTICENTER;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：314 / 331
页数：18
相关论文
共 38 条
  • [1] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
    Ascierto, Paolo A.
    Long, Georgina V.
    Robert, Caroline
    Brady, Benjamin
    Dutriaux, Caroline
    Di Giacomo, Anna Maria
    Mortier, Laurent
    Hassel, Jessica C.
    Rutkowski, Piotr
    McNeil, Catriona
    Kalinka-Warzocha, Ewa
    Savage, Kerry J.
    Hernberg, Micaela M.
    Lebbe, Celeste
    Charles, Julie
    Mihalcioiu, Catalin
    Chiarion-Sileni, Vanna
    Mauch, Cornelia
    Cognetti, Francesco
    Ny, Lars
    Arance, Ana
    Svane, Inge Marie
    Schadendorf, Dirk
    Gogas, Helen
    Saci, Abdel
    Jiang, Joel
    Rizzo, Jasmine
    Atkinson, Victoria
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 187 - 194
  • [2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [3] Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
    Brahmer, Julie R.
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Zhang, Jin
    Lubiniecki, Gregory M.
    Deitz, Anne C.
    Rangwala, Reshma
    Reck, Martin
    [J]. LANCET ONCOLOGY, 2017, 18 (12) : 1600 - 1609
  • [4] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Karbownik, Malgorzata
    Migdalska-Sek, Monika
    Pastuszak-Lewandoska, Dorota
    Wloch, Jan
    Lewinski, Andrzej
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) : 26 - 35
  • [5] Staging and Prognosis of Cutaneous Melanoma
    Dickson, Paxton V.
    Gershenwald, Jeffrey E.
    [J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 20 (01) : 1 - +
  • [6] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander C. J.
    Suciu, Stefan
    Robert, Caroline
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) : 1789 - 1801
  • [7] Lung Cancer in Africa: Challenges and Perspectives
    Gaafar, Rabab
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S115 - S116
  • [8] Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    Hamid, O.
    Robert, C.
    Daud, A.
    Hodi, F. S.
    Hwu, W. J.
    Kefford, R.
    Wolchok, J. D.
    Hersey, P.
    Joseph, R.
    Weber, J. S.
    Dronca, R.
    Mitchell, T. C.
    Patnaik, A.
    Zarour, H. M.
    Joshua, A. M.
    Zhao, Q.
    Jensen, E.
    Ahsan, S.
    Ibrahim, N.
    Ribas, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 582 - 588
  • [9] Hamid O., 2016, ANN ONCOL S, V27, p1107O
  • [10] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
    Hamid, Omid
    Robert, Caroline
    Daud, Adil
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Kefford, Richard
    Wolchok, Jedd D.
    Hersey, Peter
    Joseph, Richard W.
    Weber, Jeffrey S.
    Dronca, Roxana
    Gangadhar, Tara C.
    Patnaik, Amita
    Zarour, Hassane
    Joshua, Anthony M.
    Gergich, Kevin
    Elassaiss-Schaap, Jeroen
    Algazi, Alain
    Mateus, Christine
    Boasberg, Peter
    Tumeh, Paul C.
    Chmielowski, Bartosz
    Ebbinghaus, Scot W.
    Li, Xiaoyun Nicole
    Kang, S. Peter
    Ribas, Antoni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) : 134 - 144
1234